Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sino Biopharmaceutical Limited
  6. Summary
    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
5.64 5.69 5.55 5.5 5.7 Last
40933700 76541770 44569320 29658430 71761580 Volume
+0.36% +0.89% -2.46% -0.90% +3.64% Change
Estimated financial data (e)
Sales 2021 34 160 M 4 383 M 4 383 M
Net income 2021 11 001 M 1 411 M 1 411 M
Net cash position 2021 11 702 M 1 502 M 1 502 M
P/E ratio 2021 10,6x
Yield 2021 2,35%
Sales 2022 40 940 M 5 253 M 5 253 M
Net income 2022 7 465 M 958 M 958 M
Net cash position 2022 15 692 M 2 013 M 2 013 M
P/E ratio 2022 15,3x
Yield 2022 1,57%
Capitalization 107 B 13 718 M 13 719 M
EV / Sales 2021 2,79x
EV / Sales 2022 2,23x
Nbr of Employees 24 443
Free-Float 52,2%
More Financials
Company
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of ophthalmia and hepatitis. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.4%); - other (2.6%). 
Sector
Pharmaceuticals
Calendar
03/31Earnings Release
More about the company
Ratings of Sino Biopharmaceutical Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about SINO BIOPHARMACEUTICAL LIMITED
12/01Sino Biopharmaceutical Limited Enters into A Facility Agreement
CI
11/18Treadwell Therapeutics Inc. announced that it has received $91 million in funding from ..
CI
11/08Sino Biopharmaceutical Repurchases 5 Million Shares
MT
11/03Sino Biopharm Repurchases 3.5 Million Shares
MT
11/03Sino Biopharmaceutical Buys Back 1.7 Million Shares
MT
10/18SINO BIOPHARMACEUTICAL : Biopharm's Antibiotic Wins Marketing Approval in China
MT
10/15Sino Biopharmaceutical Limited Announces Approval for the First Generic "Colistimethate..
CI
10/08SINO BIOPHARMACEUTICAL : Anti-Tumor Drug Registration Accepted in China
MT
10/08SINO BIOPHARMACEUTICAL : Gets US FDA Nod for Clinical Trial of Cough, Pain Treatment
MT
10/08Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine "Tcr167..
CI
09/13SINO BIOPHARMACEUTICAL LIMITED : Ex-dividend day for quarterly dividend
FA
09/02SINO BIOPHARMACEUTICAL : Receives Registration Approval for Cancer Treatment in China
MT
09/02SINO BIOPHARMACEUTICAL : Gets Registration Approval for Hepatitis Treatment in China
MT
09/01Hong Kong Hang Seng Rises 0.6%, Led by Tech Sector
MT
09/01Sino Biopharmaceutical Limited Announces Sofosbuvir Tablets Obtains Drug Registration C..
CI
More news
News in other languages on SINO BIOPHARMACEUTICAL LIMITED
11/08Sino Biopharmaceutical rachète 5 millions d'actions
11/03Sino Biopharm rachète 3,5 millions d'actions
11/03Sino Biopharmaceutical rachète 1,7 million d'actions
10/18L'antibiotique de Sino Biopharm obtient l'autorisation de mise sur le marché en Chine
10/08L'enregistrement d'un médicament anti-tumoral de Sino Biopharmaceutical accepté en Chin..
More news
Analyst Recommendations on SINO BIOPHARMACEUTICAL LIMITED
More recommendations
Chart SINO BIOPHARMACEUTICAL LIMITED
Duration : Period :
Sino Biopharmaceutical Limited Technical Analysis Chart | 1177 | KYG8167W1380 | MarketScreener
Technical analysis trends SINO BIOPHARMACEUTICAL LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 5,70 HKD
Average target price 10,57 HKD
Spread / Average Target 85,4%
EPS Revisions
Managers and Directors
Yi Li Chief Executive Officer & Executive Director
Theresa Tse Chairman
Hsuan Tse General Manager-Information Management
Wei Nong Ye General Manager-Research & Development
Mao Li Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SINO BIOPHARMACEUTICAL LIMITED-24.00%13 718
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641